{"result": "(\"entity\"<|>FEARON K<|>PERSON<|>Fearon K is a researcher involved in studies related to cancer cachexia and its treatment options.)\n##\n(\"entity\"<|>ARENDS J<|>PERSON<|>Arends J is a researcher who has contributed to the understanding of cancer cachexia mechanisms and treatment.)\n##\n(\"entity\"<|>BARACOS V<|>PERSON<|>Baracos V is a researcher focused on cancer cachexia and its impact on patients with cancer.)\n##\n(\"entity\"<|>WU J<|>PERSON<|>Wu J is a researcher who studied weight loss and energy expenditure in patients with esophageal cancer.)\n##\n(\"entity\"<|>HUANG C<|>PERSON<|>Huang C is a researcher involved in the study of energy expenditure in esophageal cancer patients.)\n##\n(\"entity\"<|>XIAO H<|>PERSON<|>Xiao H is a researcher who has contributed to studies on weight loss in esophageal cancer patients.)\n##\n(\"entity\"<|>TANG Q<|>PERSON<|>Tang Q is a researcher who has worked on the nutritional aspects of esophageal cancer treatment.)\n##\n(\"entity\"<|>CAI W<|>PERSON<|>Cai W is a researcher involved in studies related to esophageal cancer and its treatment.)\n##\n(\"entity\"<|>DIAKOWSKA D<|>PERSON<|>Diakowska D is a researcher who has studied the inflammatory response in esophageal cancer and cachexia.)\n##\n(\"entity\"<|>KRZYSTEK-KORPACKA M<|>PERSON<|>Krzystek-Korpacka M is a researcher focused on the relationship between leptin and cancer cachexia.)\n##\n(\"entity\"<|>MARKOCKA-MACZKA K<|>PERSON<|>Markocka-Maczka K is a researcher who has contributed to studies on cancer cachexia and its effects.)\n##\n(\"entity\"<|>DIAKOWSKI W<|>PERSON<|>Diakowski W is a researcher involved in studies related to esophageal cancer and cachexia.)\n##\n(\"entity\"<|>MATUSIEWICZ M<|>PERSON<|>Matusiewicz M is a researcher who has studied the inflammatory response in cancer cachexia.)\n##\n(\"entity\"<|>GRABOWSKI K<|>PERSON<|>Grabowski K is a researcher focused on the effects of cancer cachexia on patients.)\n##\n(\"entity\"<|>JIANG N<|>PERSON<|>Jiang N is a researcher who has studied clinical determinants of weight loss in esophageal cancer patients.)\n##\n(\"entity\"<|>ZHAO JZ<|>PERSON<|>Zhao JZ is a researcher involved in the study of weight loss during radiotherapy for esophageal cancer.)\n##\n(\"entity\"<|>CHEN XC<|>PERSON<|>Chen XC is a researcher who has contributed to studies on weight loss in esophageal carcinoma patients.)\n##\n(\"entity\"<|>LI LY<|>PERSON<|>Li LY is a researcher focused on the clinical aspects of esophageal cancer treatment.)\n##\n(\"entity\"<|>ZHANG LJ<|>PERSON<|>Zhang LJ is a researcher involved in studies related to esophageal cancer and weight loss.)\n##\n(\"entity\"<|>ZHAO Y<|>PERSON<|>Zhao Y is a researcher who has studied the clinical determinants of weight loss in esophageal cancer patients.)\n##\n(\"entity\"<|>RIBI K<|>PERSON<|>Ribi K is a researcher who has studied the effects of chemotherapy on dysphagia in esophageal cancer patients.)\n##\n(\"entity\"<|>KOEBERLE D<|>PERSON<|>Koeberle D is a researcher involved in studies on chemotherapy and its effects on esophageal cancer.)\n##\n(\"entity\"<|>SCHULLER JC<|>PERSON<|>Schuller JC is a researcher who has contributed to studies on chemotherapy in esophageal cancer.)\n##\n(\"entity\"<|>HONEGGER H<|>PERSON<|>Honegger H is a researcher focused on the effects of chemotherapy on esophageal cancer patients.)\n##\n(\"entity\"<|>ROTH A<|>PERSON<|>Roth A is a researcher involved in studies related to esophageal cancer treatment.)\n##\n(\"entity\"<|>HESS V<|>PERSON<|>Hess V is a researcher who has studied the impact of chemotherapy on esophageal cancer patients.)\n##\n(\"entity\"<|>AWAD S<|>PERSON<|>Awad S is a researcher focused on changes in body composition following chemotherapy for esophageal cancer.)\n##\n(\"entity\"<|>TAN BH<|>PERSON<|>Tan BH is a researcher involved in studies on body composition in esophageal cancer patients.)\n##\n(\"entity\"<|>CUI H<|>PERSON<|>Cui H is a researcher who has studied the effects of chemotherapy on body composition in cancer patients.)\n##\n(\"entity\"<|>BHALLA A<|>PERSON<|>Bhalla A is a researcher focused on the impact of chemotherapy on physical fitness in cancer patients.)\n##\n(\"entity\"<|>FEARON KC<|>PERSON<|>Fearon KC is a researcher who has studied cancer cachexia and its management.)\n##\n(\"entity\"<|>PARSONS SL<|>PERSON<|>Parsons SL is a researcher involved in studies related to esophageal cancer treatment.)\n##\n(\"entity\"<|>YIP C<|>PERSON<|>Yip C is a researcher who has studied sarcopenia and body composition changes in esophageal cancer patients.)\n##\n(\"entity\"<|>GOH V<|>PERSON<|>Goh V is a researcher focused on the assessment of body composition in cancer patients.)\n##\n(\"entity\"<|>DAVIES A<|>PERSON<|>Davies A is a researcher involved in studies on body composition and clinical outcomes in esophageal cancer.)\n##\n(\"entity\"<|>GOSSAGE J<|>PERSON<|>Gossage J is a researcher who has studied the effects of chemotherapy on esophageal cancer patients.)\n##\n(\"entity\"<|>MITCHELL-HAY R<|>PERSON<|>Mitchell-Hay R is a researcher focused on the impact of chemotherapy on physical fitness in cancer patients.)\n##\n(\"entity\"<|>HYNES O<|>PERSON<|>Hynes O is a researcher involved in studies related to esophageal cancer treatment.)\n##\n(\"entity\"<|>JACK S<|>PERSON<|>Jack S is a researcher who has studied the effects of neoadjuvant chemotherapy on physical fitness in cancer patients.)\n##\n(\"entity\"<|>WEST MA<|>PERSON<|>West MA is a researcher focused on the impact of chemotherapy on survival in esophageal cancer patients.)\n##\n(\"entity\"<|>RAW D<|>PERSON<|>Raw D is a researcher involved in studies on the effects of chemotherapy on esophageal cancer patients.)\n##\n(\"entity\"<|>MARWOOD S<|>PERSON<|>Marwood S is a researcher who has studied the effects of neoadjuvant chemotherapy on cancer patients.)\n##\n(\"entity\"<|>AMBLER G<|>PERSON<|>Ambler G is a researcher focused on the impact of chemotherapy on physical fitness in cancer patients.)\n##\n(\"entity\"<|>COPE TM<|>PERSON<|>Cope TM is a researcher involved in studies related to esophageal cancer treatment.)\n##\n(\"entity\"<|>IDA S<|>PERSON<|>Ida S is a researcher who has studied changes in body composition after chemotherapy for esophageal cancer.)\n##\n(\"entity\"<|>WATANABE M<|>PERSON<|>Watanabe M is a researcher focused on the effects of chemotherapy on body composition in cancer patients.)\n##\n(\"entity\"<|>KARASHIMA R<|>PERSON<|>Karashima R is a researcher involved in studies on body composition changes in esophageal cancer patients.)\n##\n(\"entity\"<|>IMAMURA Y<|>PERSON<|>Imamura Y is a researcher who has studied the impact of chemotherapy on body composition in cancer patients.)\n##\n(\"entity\"<|>ISHIMOTO T<|>PERSON<|>Ishimoto T is a researcher focused on the effects of chemotherapy on cancer patients.)\n##\n(\"entity\"<|>BABA Y<|>PERSON<|>Baba Y is a researcher involved in studies related to body composition changes in cancer patients.)\n##\n(\"entity\"<|>TUCA A<|>PERSON<|>Tuca A is a researcher who has studied the clinical evaluation and management of cancer cachexia.)\n##\n(\"entity\"<|>JIMENEZ-FONSECA P<|>PERSON<|>Jimenez-Fonseca P is a researcher focused on the management of cancer cachexia.)\n##\n(\"entity\"<|>GASCÓN P<|>PERSON<|>Gascón P is a researcher involved in studies related to cancer cachexia management.)\n##\n(\"entity\"<|>MILLER KR<|>PERSON<|>Miller KR is a researcher who has studied nutrition therapy issues in esophageal cancer.)\n##\n(\"entity\"<|>BOZEMAN MC<|>PERSON<|>Bozeman MC is a researcher focused on nutrition therapy for cancer patients.)\n##\n(\"entity\"<|>MARIE T<|>PERSON<|>Marie T is a researcher involved in studies on nutrition support in cancer patients.)\n##\n(\"entity\"<|>LLOP-TALAVERON JM<|>PERSON<|>Llop-Talaveron JM is a researcher who has studied artificial nutritional support in cancer patients.)\n##\n(\"entity\"<|>FARRAN-TEIXIDOR L<|>PERSON<|>Farran-Teixidor L is a researcher focused on nutritional support in cancer patients.)\n##\n(\"entity\"<|>BADIA-TAHULL MB<|>PERSON<|>Badia-Tahull MB is a researcher involved in studies on nutritional support for cancer patients.)\n##\n(\"entity\"<|>VIRGILI-CASAS M<|>PERSON<|>Virgili-Casas M is a researcher who has studied nutritional support in cancer patients.)\n##\n(\"entity\"<|>LEIVA-BADOSA E<|>PERSON<|>Leiva-Badosa E is a researcher focused on artificial nutritional support in cancer patients.)\n##\n(\"entity\"<|>GALÁN-GUZMÁN MC<|>PERSON<|>Galán-Guzmán MC is a researcher involved in studies on nutritional support for cancer patients.)\n##\n(\"entity\"<|>COOLS-LARTIGUE J<|>PERSON<|>Cools-Lartigue J is a researcher who has studied the management of dysphagia in esophageal cancer patients.)\n##\n(\"entity\"<|>JONES D<|>PERSON<|>Jones D is a researcher focused on the management of dysphagia in cancer patients.)\n##\n(\"entity\"<|>SPICER J<|>PERSON<|>Spicer J is a researcher involved in studies on dysphagia management in esophageal cancer patients.)\n##\n(\"entity\"<|>ZOURIKIAN T<|>PERSON<|>Zourikian T is a researcher who has studied the management of dysphagia in cancer patients.)\n##\n(\"entity\"<|>ROUSSEAU M<|>PERSON<|>Rousseau M is a researcher focused on the management of dysphagia in esophageal cancer patients.)\n##\n(\"entity\"<|>ECKERT E<|>PERSON<|>Eckert E is a researcher involved in studies on dysphagia management in cancer patients.)\n##\n(\"entity\"<|>FIETKAU R<|>PERSON<|>Fietkau R is a researcher who has studied enteral nutrition in cancer patients undergoing treatment.)\n##\n(\"entity\"<|>LEWITZKI V<|>PERSON<|>Lewitzki V is a researcher focused on enteral nutrition for cancer patients.)\n##\n(\"entity\"<|>KUHNT T<|>PERSON<|>Kuhnt T is a researcher involved in studies on nutrition for cancer patients.)\n##\n(\"entity\"<|>HÖLSCHER T<|>PERSON<|>Hölscher T is a researcher who has studied nutrition therapy in cancer patients.)\n##\n(\"entity\"<|>HESS CF<|>PERSON<|>Hess CF is a researcher focused on nutrition therapy for cancer patients.)\n##\n(\"entity\"<|>BERGER B<|>PERSON<|>Berger B is a researcher involved in studies on nutrition for cancer patients.)\n##\n(\"entity\"<|>LIGHTHART-MELIS GC<|>PERSON<|>Lighthart-Melis GC is a researcher who has studied intensive nutritional support in cancer patients.)\n##\n(\"entity\"<|>WEIJS PJ<|>PERSON<|>Weijs PJ is a researcher focused on nutritional support for cancer patients.)\n##\n(\"entity\"<|>TE BOVELDT ND<|>PERSON<|>Te Boveldt ND is a researcher involved in studies on nutrition for cancer patients.)\n##\n(\"entity\"<|>BUSKERMOLEN S<|>PERSON<|>Buskermolen S is a researcher who has studied nutrition therapy in cancer patients.)\n##\n(\"entity\"<|>EARTHMAN CP<|>PERSON<|>Earthman CP is a researcher focused on nutritional support for cancer patients.)\n##\n(\"entity\"<|>VERHEUL HM<|>PERSON<|>Verheul HM is a researcher involved in studies on nutrition for cancer patients.)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 83:248-52.\n\n69. Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer ca-chexia. Nat Rev Clin Oncol. 2013; 10:90-9.\n\n70. Wu J, Huang C, Xiao H, Tang Q, Cai W. Weight loss and resting energy expenditure in male pa-tients with newly diagnosed esophageal cancer. Nutrition. 2013; 29:1310-4.\n\n71. Diakowska D, Krzystek-Korpacka M, Markoc-ka-Maczka K, Diakowski W, Matusiewicz M, Gra-bowski K. Circulating leptin and inflammatory response in esophageal cancer, esophageal can-cer-related cachexia-anorexia syndrome (CAS) and non-malignant CAS of the alimentary tract. Cytokine. 2010; 51:132-7.\n\n72. Jiang N, Zhao JZ, Chen XC, Li LY, Zhang LJ, Zhao Y. Clinical determinants of weight loss in patients with esophageal carcinoma during radiotherapy: a prospective longitudinal view. Asian Pac J Cancer Prev. 2014; 15:1943-8.\n\n73. Ribi K, Koeberle D, Schuller JC, Honegger H, Roth A, Hess V, et al. Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradia-tion? Support Care Cancer. 2009; 17:1109-16.\n\n74. Awad S, Tan BH, Cui H, Bhalla A, Fearon KC, Par-sons SL, et al. Marked changes in body composi-tion following neoadjuvant chemotherapy for oe-sophagogastric cancer. Clin Nutr. 2012; 31:74-7.\n\n75. Yip C, Goh V, Davies A, Gossage J, Mitchell-Hay R, Hynes O, et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical out-comes in oesophageal cancer. Eur Radiol. 2014; 24:998-1005.\n\n76. Jack S, West MA, Raw D, Marwood S, Ambler G, Cope TM, et al. The effect of neoadjuvant chemo-therapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. Eur J Surg Oncol. 2014;40:1313-20.\n---\n632      BLOQUE: NUTRICIÓN EN ONCOLOGÍA\n\n77. Ida S, Watanabe M, Karashima R, Imamura Y, Ishi-\n    moto T, Baba Y, et al. Changes in body composi-\n    tion secondary to neoadjuvant chemotherapy for\n    advanced esophageal cancer are related to the oc-\n    currence of postoperative complications after eso-\n    phagectomy. Ann Surg Oncol. 2014; 21:3675-9.\n78. Tuca A, Jimenez-Fonseca P, Gascón P. Clinical eva-\n    luation and optimal management of cancer ca-\n    chexia. Crit Rev Oncol Hematol. 2013; 88:625-36.\n79. Miller KR, Bozeman MC. Nutrition therapy issues in\n    esophageal cancer. Curr Gastroenterol Rep. 2012;\n    14:356-66.\n80. Mariette C, De Botton ML, Piessen G. Surgery in\n    esophageal and gastric cancer patients: what is\n    the role for nutrition support in your daily practi-\n    ce? Ann Surg Oncol. 2012; 19:2128-34.\n81. Llop-Talaveron JM, Farran-Teixidor L, Badia-Tahull\n    MB, Virgili-Casas M, Leiva-Badosa E, Galán-Guz-\n    mán MC, et al. Artificial nutritional support in can-\n    cer patients after esophagectomy: 11 years of ex-\n    perience. Nutr Cancer. 2014; 66:1038-46.\n82. Cools-Lartigue J, Jones D, Spicer J, Zourikian T,\n    Rousseau M, Eckert E, et al. Management of Dys-\n    phagia in Esophageal Adenocarcinoma Patients\n    Undergoing Neoadjuvant Chemotherapy: Can In-\n    vasive Tube Feeding be Avoided? Ann Surg Oncol.\n    2015; 22:1858-65.\n83. Fietkau R, Lewitzki V, Kuhnt T, Hölscher T, Hess CF,\n    Berger B, et al. A disease-specific enteral nutrition\n    formula improves nutritional status and functional\n    performance in patients with head and neck and\n    esophageal cancer undergoing chemoradiothera-\n    py: results of a randomized, controlled, multicen-\n    ter trial. Cancer. 2013; 119:3343-53.\n84. Ligthart-Melis GC, Weijs PJ, te Boveldt ND, Busker-\n    molen S, Earthman CP, Verheul HM, et al. Dieti-\n    cian-delivered intensive nutritional support is asso-\n    ciated with a decrease in severe postoperative\n    complications after surgery in patients\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>CANCER CACHEXIA<|>EVENT<|>Cancer cachexia is a syndrome characterized by weight loss, muscle wasting, and decreased appetite, often seen in patients with advanced cancer, particularly esophageal cancer.)\n##\n(\"entity\"<|>ESOPHAGEAL CANCER<|>EVENT<|>Esophageal cancer is a type of cancer that occurs in the esophagus, the tube that carries food from the throat to the stomach, and is often associated with significant weight loss and nutritional challenges.)\n##\n(\"entity\"<|>NEOADJUVANT CHEMOTHERAPY<|>EVENT<|>Neoadjuvant chemotherapy is a treatment given before the main treatment, often surgery, to shrink tumors in patients with esophageal cancer.)\n##\n(\"entity\"<|>NUTRITION THERAPY<|>EVENT<|>Nutrition therapy involves dietary interventions to improve the nutritional status of cancer patients, particularly those undergoing treatment for esophageal cancer.)\n##\n(\"entity\"<|>ANNALS OF SURGICAL ONCOLOGY<|>ORGANIZATION<|>Annals of Surgical Oncology is a peer-reviewed medical journal that publishes research related to surgical oncology, including studies on esophageal cancer and its treatment.)\n##\n(\"entity\"<|>NUTRITION<|>ORGANIZATION<|>Nutrition is a field of study and practice focused on dietary needs and interventions, particularly important in managing cancer cachexia and supporting patients undergoing treatment.)\n##\n(\"entity\"<|>CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY<|>ORGANIZATION<|>Critical Reviews in Oncology Hematology is a journal that publishes reviews on various aspects of oncology and hematology, including cancer cachexia management.)\n##\n(\"entity\"<|>EUROPEAN JOURNAL OF SURGICAL ONCOLOGY<|>ORGANIZATION<|>European Journal of Surgical Oncology is a journal that focuses on surgical oncology research, including studies on esophageal and gastric cancer.)\n##\n(\"entity\"<|>NUTRITION AND CANCER<|>ORGANIZATION<|>Nutrition and Cancer is a journal that publishes research on the relationship between nutrition and cancer, including studies on nutritional support for cancer patients.)\n##\n(\"entity\"<|>ASIAN PACIFIC JOURNAL OF CANCER PREVENTION<|>ORGANIZATION<|>Asian Pacific Journal of Cancer Prevention is a journal that publishes research on cancer prevention and treatment, including studies related to esophageal cancer.)\n##\n(\"relationship\"<|>CANCER CACHEXIA<|>ESOPHAGEAL CANCER<|>Cancer cachexia is a common syndrome experienced by patients suffering from esophageal cancer, leading to significant weight loss and muscle wasting.<|>8)\n##\n(\"relationship\"<|>NEOADJUVANT CHEMOTHERAPY<|>ESOPHAGEAL CANCER<|>Neoadjuvant chemotherapy is often used as a treatment approach for patients diagnosed with esophageal cancer to reduce tumor size before surgery.<|>7)\n##\n(\"relationship\"<|>NUTRITION THERAPY<|>CANCER CACHEXIA<|>Nutrition therapy is critical in managing cancer cachexia, aiming to improve the nutritional status of patients experiencing weight loss and muscle wasting.<|>9)\n##\n(\"relationship\"<|>NUTRITION THERAPY<|>ESOPHAGEAL CANCER<|>Nutrition therapy is essential for patients with esophageal cancer to address the nutritional challenges posed by the disease and its treatment.<|>8)\n##\n(\"relationship\"<|>ANNALS OF SURGICAL ONCOLOGY<|>NEOADJUVANT CHEMOTHERAPY<|>Research published in the Annals of Surgical Oncology often discusses the effectiveness and outcomes of neoadjuvant chemotherapy in surgical oncology.<|>6)\n##\n(\"relationship\"<|>CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY<|>CANCER CACHEXIA<|>Critical Reviews in Oncology Hematology publishes reviews that may include management strategies for cancer cachexia in oncology patients.<|>5)\n##\n(\"relationship\"<|>EUROPEAN JOURNAL OF SURGICAL ONCOLOGY<|>NEOADJUVANT CHEMOTHERAPY<|>The European Journal of Surgical Oncology features studies on the role of neoadjuvant chemotherapy in surgical outcomes for cancer patients.<|>6)\n##\n(\"relationship\"<|>NUTRITION AND CANCER<|>NUTRITION THERAPY<|>Nutrition and Cancer publishes research on the impact of nutrition therapy on cancer treatment outcomes, including cachexia management.<|>7)\n##\n(\"relationship\"<|>ASIAN PACIFIC JOURNAL OF CANCER PREVENTION<|>ESOPHAGEAL CANCER<|>The Asian Pacific Journal of Cancer Prevention includes studies related to the prevention and management of esophageal cancer.<|>5)\n<|COMPLETE|>"}]}